Mesoblast Ltd
ASX:MSB
Mesoblast Ltd
Revenue
Mesoblast Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mesoblast Ltd
ASX:MSB
|
Revenue
$7.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
ASX:IMM
|
Revenue
AU$256.6k
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-24%
|
|
CSL Ltd
ASX:CSL
|
Revenue
$14.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Revenue
AU$87.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
25%
|
CAGR 10-Years
42%
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Revenue
AU$502.5m
|
CAGR 3-Years
359%
|
CAGR 5-Years
381%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Revenue
AU$21.5m
|
CAGR 3-Years
99%
|
CAGR 5-Years
377%
|
CAGR 10-Years
32%
|
See Also
What is Mesoblast Ltd's Revenue?
Revenue
7.5m
USD
Based on the financial report for Dec 31, 2023, Mesoblast Ltd's Revenue amounts to 7.5m USD.
What is Mesoblast Ltd's Revenue growth rate?
Revenue CAGR 5Y
-14%
Over the last year, the Revenue growth was -19%. The average annual Revenue growth rates for Mesoblast Ltd have been -23% over the past three years , -14% over the past five years .